Skip to main content
Top
Published in: Medical Oncology 2/2012

01-06-2012 | Original Paper

MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2

Authors: Chang Zheng, Sun Yinghao, Jiao Li

Published in: Medical Oncology | Issue 2/2012

Login to get access

Abstract

The aim of this study is to evaluate the effect of the variation of miR-221 on the prostate cancer cells’ NE differentiation and invasive function and to examine the function of miR-221 in plasma as a blood-based miRNA biomarker candidate for CaP. The expression of 7 miRNAs in LNCaP, LNCaP-AI, and PC3 prostate cancer cell lines was detected by Northern blotting. LNCaP and LNCaP-AI cells cultured in androgen-depleted medium were transfected with different synthetic miRs. The ability of invasiveness was evaluated by a Matrigel invasion assay. Cell growth was assessed by using the CCK-8 cell proliferation assay at different times. The expression of NSE and DVL2 during the neuroendocrine phenotype and migration were measured by qRT–PCR and Western blot. The level of miR-221 in the prostate cancer samples was measured by qRT–PCR. MiR-221 was significantly increased compared AIPC with ADPC cell lines. Overexpression of miR-221 in LNCaP cells significantly increased the level of NSE expression and induced NE differentiation. Knocking down the level of miR-221 expression with antagonist miR-221 in the LNCaP-AI cell line increased migration and invasion (P < 0.01). DVL2 protein level was up-regulated after transfection of anti-miR-221. MiR-221 was up-regulated in CaP plasma (P < 0.01). We demonstrate a significant difference in miR-221 expression between ADPC and AIPC. MiR-221 may contribute to NE differentiation, which may be the cause for AIPC. We also suggest that miR-221 may control the migration of AIPC cells through DVL2, working as a key regulator in advanced CaP. The role of miR-221 in other target mRNA needs to be further investigated.
Literature
1.
go back to reference Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2007;57:43–66.PubMedCrossRef Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2007;57:43–66.PubMedCrossRef
2.
go back to reference Pienta KJ, Bradley D. Mechanisms underlying the development of androgen- independent prostate cancer. Clin Cancer Res. 2006;12:1665–71.PubMedCrossRef Pienta KJ, Bradley D. Mechanisms underlying the development of androgen- independent prostate cancer. Clin Cancer Res. 2006;12:1665–71.PubMedCrossRef
4.
go back to reference Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 2007;8:93–103.PubMedCrossRef Chen K, Rajewsky N. The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 2007;8:93–103.PubMedCrossRef
5.
6.
go back to reference Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004;23:4051–60.PubMedCrossRef Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004;23:4051–60.PubMedCrossRef
7.
go back to reference Ambs S, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008;68:6162–70.PubMedCrossRef Ambs S, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008;68:6162–70.PubMedCrossRef
8.
go back to reference Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA, Farace MG. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 2007;282:23716–24.PubMedCrossRef Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA, Farace MG. miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem. 2007;282:23716–24.PubMedCrossRef
9.
10.
go back to reference Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009;69:3356–63.PubMedCrossRef Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009;69:3356–63.PubMedCrossRef
11.
go back to reference Di Sant’Agnese PA, de Mesy Jensen KL. Human prostatic endocrineparacrine (APUD) cells. Distributional analysis with a comparison of serotonin and neuron- specific enolase immunoreactivity and silver stains. Arch Path Lab Med. 1985;109:607–12.PubMed Di Sant’Agnese PA, de Mesy Jensen KL. Human prostatic endocrineparacrine (APUD) cells. Distributional analysis with a comparison of serotonin and neuron- specific enolase immunoreactivity and silver stains. Arch Path Lab Med. 1985;109:607–12.PubMed
12.
go back to reference Cox ME, Deeble PD, Lakhani S, Parsons SJ. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression. Cancer Res. 1999;59:3821–30.PubMed Cox ME, Deeble PD, Lakhani S, Parsons SJ. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression. Cancer Res. 1999;59:3821–30.PubMed
13.
go back to reference Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology. 1998;51:585–9.PubMedCrossRef Jiborn T, Bjartell A, Abrahamsson PA. Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. Urology. 1998;51:585–9.PubMedCrossRef
14.
go back to reference Tso CL, et al. Androgen deprivation induces selective outgrowth of aggressive hormone refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J. 2000;6:220–33.PubMed Tso CL, et al. Androgen deprivation induces selective outgrowth of aggressive hormone refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J. 2000;6:220–33.PubMed
15.
go back to reference Calin GA, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99:15524–9.PubMedCrossRef Calin GA, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99:15524–9.PubMedCrossRef
16.
go back to reference Bonci D, et al. The miR-15a-miR-16–1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14:1271–7.PubMedCrossRef Bonci D, et al. The miR-15a-miR-16–1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14:1271–7.PubMedCrossRef
17.
go back to reference Varambally S, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008;322:1695–9.PubMedCrossRef Varambally S, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008;322:1695–9.PubMedCrossRef
18.
go back to reference Li T, Li D, Sha J, Sun P, Huang Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun. 2009;383:280–5.PubMedCrossRef Li T, Li D, Sha J, Sun P, Huang Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun. 2009;383:280–5.PubMedCrossRef
19.
go back to reference Gandellini P, et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 2009;69:2287–95.PubMedCrossRef Gandellini P, et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 2009;69:2287–95.PubMedCrossRef
20.
go back to reference Shi XB, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen independent growth of prostate cancer cells. Proc Natl Acad Sci USA. 2007;104:19983–8.PubMedCrossRef Shi XB, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen independent growth of prostate cancer cells. Proc Natl Acad Sci USA. 2007;104:19983–8.PubMedCrossRef
21.
go back to reference Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 2004;351:1488–90.PubMedCrossRef Debes JD, Tindall DJ. Mechanisms of androgen-refractory prostate cancer. N Engl J Med. 2004;351:1488–90.PubMedCrossRef
22.
go back to reference Mercatelli N, et al. The inhibition of the highly expressed miR-221 and miR- 222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE. 2008;3:e4029.PubMedCrossRef Mercatelli N, et al. The inhibition of the highly expressed miR-221 and miR- 222 impairs the growth of prostate carcinoma xenografts in mice. PLoS ONE. 2008;3:e4029.PubMedCrossRef
23.
go back to reference Bejsovec A. Wnt pathway activation: New relations and locations. Cell. 2005;120:11–4.PubMed Bejsovec A. Wnt pathway activation: New relations and locations. Cell. 2005;120:11–4.PubMed
24.
go back to reference Cong F, Varmus H. Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of β-catenin. Proc Natl Acad Sci USA. 2004;101:2882–7.PubMedCrossRef Cong F, Varmus H. Nuclear-cytoplasmic shuttling of Axin regulates subcellular localization of β-catenin. Proc Natl Acad Sci USA. 2004;101:2882–7.PubMedCrossRef
25.
go back to reference Mitchell PS, Rachael K, et al. Circulating microRNAs as stable blood-based markers for cancer detection Proc Natl Acad Sci USA. 2008;105:10513–8. Mitchell PS, Rachael K, et al. Circulating microRNAs as stable blood-based markers for cancer detection Proc Natl Acad Sci USA. 2008;105:10513–8.
Metadata
Title
MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2
Authors
Chang Zheng
Sun Yinghao
Jiao Li
Publication date
01-06-2012
Publisher
Springer US
Published in
Medical Oncology / Issue 2/2012
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9934-8

Other articles of this Issue 2/2012

Medical Oncology 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.